USPTO serial 98699055
GO BEYOND
Reviewed by CopyMark Law Group
Status 731Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- KETCHUM, BRENDAN J
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with GO BEYOND?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,545*
Plus Government fees of $750
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John A. Yates
John A. Yates Patterson + Sheridan, LLP24 Greenway PlazaSuite 1600Houston, TX 77046Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for weight management, hormone replacement therapy, intravenous nutrition, dietary nutrition, mental health, skin care, sexual dysfunction, fertility, men's health, women's health, and gender-affirming care; pharmaceutical preparations for intravenous therapy, namely, amino acids, minerals, vitamins, antihistamines, and anesthetics prepared for direct administration into a vein; pharmaceutical preparations for intravenous therapy for treatment of inflammation, pain, blood clots, nausea, and vomiting; pharmaceutical preparations for injectable therapy, namely, amino acids, minerals, vitamins, antihistamines, and anesthetics prepared for administration from a needle; pharmaceutical preparations for injectable therapy for treatment of inflammation, pain, blood clots, nausea, and vomiting; pharmaceutical preparations for the prevention, reduction, and treatment of cardiovascular, lymphatic, respiratory, pulmonary, neurological, renal, gastrointestinal, musculoskeletal, dermatological, allergic, inflammatory, autoimmune, gynecological, genetic, longevity, metabolic, and pain conditions; disinfecting wipes; and sanitizing wipes. | ACTIVE | — |
| 010 | Medical syringes; disposable syringes; syringe barrels; luer lock syringe barrels; injection needles for medical use; vial adapters for syringes; trocars; and containers adapted for the disposal of medical instruments and syringes. | ACTIVE | — |
| 040 | Custom manufacture of pharmaceuticals; contract manufacturing of pharmaceuticals; contract manufacturing for others; contract manufacturing for others in the field of pharmacology, microbiology, toxicology, and biotechnology. | ACTIVE | — |
| 042 | Pharmaceutical drug development services and contract pharmaceutical drug development services; Research and development services of pharmaceutical products and preparations; Research and development services of pharmaceutical products and preparations for others; Conducting research, formulation development, clinical trials, packaging design sevices, and quality assurance for others in the pharmaceutical industry in the field of pharmaceuticals; Conducting post-marketing product support for others in the pharmaceutical industry in the field of pharmaceuticals, namely, post-market surveillance, clinical trials, and studies to further assess the safety, efficacy, or optimal use of approved products; Laboratory research services and contract research services, namely, analytical and microbiological testing for others in the pharmaceutical industry; Laboratory analysis for others in the field of pharmaceuticals; Laboratory services in the fields of pharmacology, microbiology, toxicology, and biotechnology; Testing and analysis of pharmaceuticals per industry standards and for compliance with the requirements of the United States Pharmacopeia regulatory requirements; Quality control testing for others in the pharmaceutical industry; Quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of pharmacology, microbiology, toxicology, and biotechnology; Testing of pharmaceutical raw materials to determine conformity with established regulatory standards. | ACTIVE | — |
| 045 | Conducting regulatory compliance consulting for others in the pharmaceutical industry in the field of pharmaceuticals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Empower Clinic Services, L.L.C.
- Other trademarks owned by Empower Clinic Services, L.L.C.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named GO BEYOND
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 24, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 24, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 24, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 31, 2026 | NOAC | CORRECTED NOA E-MAILED | — |
| Aug 31, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 31, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Aug 30, 2026 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Aug 27, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 15, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jul 15, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 15, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 15, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 22, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 20, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 15, 2026 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Jan 15, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 15, 2026 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Jan 15, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 15, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 20, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 20, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 14, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 22, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 25, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 24, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 24, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 23, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 23, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 23, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 22, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 22, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 22, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 19, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 15, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 14, 2024 | NWAP | NEW APPLICATION ENTERED | — |